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In the present study, we demonstrate for the first time the presence of important concentrations of EGF binding sites 
in isolated epithelial cells of both human fetal small intestine and colon as early as 12 weeks gestation. The pattern of 
EGF binding in the small intestine between 12 and 17 weeks show that binding was significantly higher (2.5fold) in 
younger fetuses than in older fetuses. Moreover, the fetal colon exhibited a much higher binding capacity (I .5-2.5 times) 
than corresponding intestinal cells for all age groups studied. Analysis of Scatchard representations reveal that the con- 
centration of high- and low-affinity binding sites in colonic epithelial cells are twice the values observed in corresponding 
intestinal cells. The present data raise interesting possibilities as to the role of this growth factor in human fetal gut 
development. 
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1. INTRODUCTION 
Epidermal growth factor (EGF), a potent 
53-amino acid single-chain polypeptide, has fast 
become one of the better characterized growth fac- 
tors and has been identified in a number of 
biological fluids and tissues [l-4]. In man, recent 
immunohistochemical localization of EGF in 
several fetal tissues such as submandibular gland, 
kidney and developing gut seems to indicate that 
this growth factor may already exert possible ex- 
ocrine or paracrine functions early in human 
development [5, 61. Moreover, significant concen- 
trations of EGF have been detected in amniotic 
fluid (0.25-4.3 ng/ml) as early as 16 weeks gesta- 
tion and may derive from endogenous sources 
[6-81. This peptide has already been shown to in- 
fluence both fetal and neonatal gastrointestinal 
tissues in rodents (9-111 and may therefore also 
play a role in fetal development of the human GI 
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tract. However, any possible effect of EGF on 
these tissues requires the presence of specific EGF 
receptors on their cell surface. In a previous 
report, we were able to isolate, in a complete and 
selective manner, epithelial cells of both fetal in- 
testine and colon, regardless of their stage of 
development [12]. Using these pure cell prepara- 
tions, we have established the presence of specific 
EGF receptors in both small intestine and colon of 
12-17-week-old fetuses. 
2. MATERIALS AND METHODS 
2.1. Tissue specimens and cell preparations 
Small intestine and/or colon from over 31 fetuses ranging 
from 12 to 17 weeks in age (post-fertilization) were obtained 
after legal abortion. Epithelial cell preparations were obtained 
by manual shaking of everted segments of small intestine or col- 
on in a 1.5 nM EDTA-0.25 M NaCl solution at 4°C as de- 
scribed in (121. Ahquots of the resulting cell suspensions were 
put aside for protein determination by the method of Lowry et 
al. [13]. 
2.2. EGF iodination 
Receptor-grade mouse EGF (Collaborative Research, 
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Waltham, MA) was iodinated by the chloramine-T method and 
separated on an AC-1 ion-exchange resin column as described 
[14, 151. Specific activity ranged between 350 and 39O&i/pg. 
2.3. Binding measurements 
Cell suspensions (0.06-1.0 mg/ml) were incubated with 
2 x lO_” M ‘251-EGF (approx. 50000 cpm) in Krebs’ Ringer 
phosphate (KRP) buffer + 2% bovine serum albumin. Non- 
specific binding was determined by adding 10m6 M native EGF. 
Incubation was carried out in duplicate samples for 45 min at 
22°C unless stated otherwise. Cell-bound labelled EGF was 
then separated by rapid centrifugation (15000 x g in 1 min) 
and counted in a Beckman autogamma scintillation spec- 
t:ometer. Specific binding is obtained by subtracting non- 
specific binding from the total radioactivity bound. 
For Scatchard analyses, cells were incubated with 2 x lo-” 
M “‘I-EGF and increasing concentrations of unlabelled EGF 
(lo-‘i-10-’ M). The non-linear Scatchard plots were analyzed 
according to the two-site model [14] by an iterative process for 
non-linear regression. Equilibrium parameters of the non-linear 
function (Ki, Kz, n, and n2) were estimated by the least squares 
method using a pseudo-Gauss-Newton algorithm. The 
predicted values were calculated as described [15, 161. 
3. RESULTS 
3.1. Kinetics and specificity of EGF binding 
As shown in fig. 1, rz51-EGF binding to isolated 
epithelial cells was found to be time and 
temperature-dependent (left panel). At 37’C, max- 
imal binding was achieved quickly (20 min), but 
decreased sharply soon afterwards. At 22°C 
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Fig. 1. Association and dissociation kinetics of ‘251-EGF binding 
to isolated intestinal epithelial cells. In panel A, cells (0.4-0.7 
mg cell protein/ml) were incubated with 2 x lo-” M “‘I-EGF 
at 22°C (A) or 37°C (A) for the time intervals indicated. In 
panel B, after 45 min incubation at 22”C, dissociation was in- 
itiated by dilution (20-fold) of the incubation medium in the 
presence (0) or absence (0) lo-’ M unlabelled EGF. The re- 
maining radioactivity bound is plotted as % of initial binding 
vs time. Each point represents the mean of two separate ex- 
periments, in duplicate determinations. 
binding increased gradually with time to reach a 
plateau after 45 min of incubation. This steady- 
state binding was readily reversible by subsequent 
dilution and/or addition of non-radioactive EGF 
in the incubation medium (right panel). After 90 
min post-incubation at 22”C, over 80% of bound 
labelled EGF was readily dissociated from its 
receptor after addition of cold EGF (half-time: 20 
min), thus indicating that very little internalization 
of the ligand-receptor complex had occurred. 
Therefore, all subsequent binding experiments 
were performed at 22°C for 45 min. Specificity of 
EGF binding was also tested by addition, in excess 
concentrations, of various hormones or growth 
factors into the incubation medium. As seen in 
table 1, no cross-competition was observed be- 
tween lz51-EGF and all tested steroid or peptidic 
hormones. Only insulin-growth-factor II (10e6 M) 
competed slightly for EGF binding sites. 
3.2. Comparative development pattern of EGF 
binding 
Specific binding patterns of “‘I-EGF to isolated 
intestinal and colonic epithelial cells as a function 
of gestational age is shown in fig.2. In the small in- 
testine, binding was highest between 12 and 14 
weeks of age (2.24-2.86 pmol/mg cell protein) and 
decreased steadily afterwards (1.13 pmol/mg pro- 
tein at 17 weeks). In percentage terms, specific 
binding in younger fetuses represented more than 
TABLE 1 
Addition 
Specificity of “‘1-EGF binding 
Concentration Specific binding 
(M) Expt 1 Expt 2 Expt 3 
None 2132 2001 1721 
EGF 10-6 579 590 433 
Insulin 10-6 2188 2076 1899 
ACTH 10-s 2307 ND 1864 
Thyroxine 10-s 2169 2149 1538 
Hydrocorticosone 10-6 2029 1803 1478 
IGF-I 1o-6 2041 1863 1483 
IGF-II 1o-6 1517 1763 1206 
Dexamethasone 10-S ND 1923 ND 
The hormones or analogues indicated were added simultaneous- 
ly with 2 x IO-” M labelled EGF to isolated intestinal 
epithelial cells for 45 min at 22°C. Cells were obtained from 
fetuses aged 14-16 weeks. Values for each experiment are the 
mean of duplicate determinations and are expressed in cpm. 
ND, not determined 
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Fig.2. Developmental pattern of specific ‘251-EGF binding in 
isolated intestinal (o---+) and colonic (A---A) epithelial cells 
of human fetuses aged between 12 and 17 weeks. Cells were in- 
cubated at 22°C for 45 min. The number of experiments is in- 
dicated above each point. 
16.5% of labelled EGF/mg cell protein whereas 
17-week-old fetuses bound less than 6% of labelled 
EGF per mg cell protein. When incubated under 
the same optimal conditions, isolated colonic 
epithelial cells demonstrated the same pattern of 
high-binding capacity between 12 and 14 weeks 
and gradual diminished binding thereafter (fig.2). 
However, compared to the small intestine, specific 
binding in the colon was substantially higher 
(1.4-2.4-times higher) in all age groups studied. At 
12 weeks, colonic cells bound 4.43 pmol labelled 
EGF (23.4%/mg protein) while at 17 weeks, cells 
bound 2.75 pmol labelled EGF (14.5%/mg pro- 
tein). 
3.3. Characteristics of EGF binding 
Scatchard plots of bound “‘1-EGF displacement 
by increasing concentrations of native EGF were 
performed in both intestinal and colonic epithelial 
cells for which an example is given in fig.3. Both 
cell populations exhibited two classes of binding 
sites for low- and high-affinity binding. At 
equilibrium, the association constants Ki (high- 
affinity) and K2 (low-affinity) for EGF binding re- 
mained relatively similar between intestinal and 
colonic epithelia. In intestinal cells, Ki and KZ 
values were 1.90 f 0.45 and 0.033 + 0.016 x lo9 
M-l, respectively (mean f SE, n = 5), while in 
colonic cells, mean values for the constants K1 and 
K2 were 1.78 + 0.83 and 0.014 +- 0.005 x lo9 
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Fig.3. Representative Scatchard plots of bound ‘251-EGF 
displacement by unlabelled EGF in isolated intestinal (top 
panel) and colonic (bottom panel) epithelial cells. Bound vs free 
(B/F) EGF is plotted against bound (B) EGF. (A) Experimental 
values, (A) predicted values. Corresponding equilibrium 
parameters for high (Ki, nr)- and low (Kz, nz)-affinity binding 
sites are given for each plot. Affinity constants (Kr, &) are ex- 
pressed as 10’ M-’ while concentration of binding sites (nr, n2) 
are expressed as pmol per mg cell protein. 
M-l, respectively (n = 3). On the other hand, the 
concentrations of EGF binding sites (ni, n2) were 
higher in colonic epithelial cells (126 + 79 and 
1394 k 302 pmol/mg cell protein) compared to 
those found in intestinal epithelial cells (61 + 10 
and 487 f 252 pmol/mg cell protein). 
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4. DISCUSSION 
The present study establishes the presence of 
specific EGF receptors in both intestinal and col- 
onic epithelial cells of the human fetus. The 
characteristics of these receptors in terms of 
binding kinetics, ligand specificity and binding af- 
finities (& = 10-10-10-9 M) are typical of those 
found in rodent intestinal epithelial cells [14, 171. 
Unfortunately, very little data exist concerning 
EGF receptors in human gut tissues, especially 
during fetal life. The only developmental profiles 
of EGF receptors that are available are limited to 
postnatal development in rodents in which recep- 
tor ontogeny has been characterized in both small 
intestinal [ 15, 181 and colonic [ 161 epithelium. In 
the human fetus, of particular interest is the 
binding patterns each of these two tissues reflect 
during development and, in particular, the time- 
frames in which they occur. Between 8 and 12 
weeks of fetal life, the small intestine undergoes 
extensive morphogenesis with the onset of villous 
and crypt formation and subsequent ransforma- 
tion of the epithelium from pseudostratified col- 
umnar to simple columnar [ 191. Labelling indices 
within this epithelium are also at their highest 
value between 8 and 10 weeks gestation (approx. 
26-30070) and decrease markedly during the next 
4-6 weeks 1201. Interestingly, it is during this 
critical period of morphogenesis and differentia- 
tion that the intestinal epithelium exhibits its 
highest EGF binding capabilities (fig.2). 
Moreover, Poulsen and co-workers [6] have 
recently demonstrated the presence of im- 
munoreactive EGF in intestinal Paneth cells of the 
20-week-old fetus. Paneth cells normally appear at 
approximately 11-12 weeks gestation [20]. If these 
Paneth cells are indeed able to synthesize an active 
form of EGF, then the appearance of endogenous 
sources of this growth factor coincides well with 
the high number of EGF receptors of both gut 
tissues at this early age. The pattern of EGF 
binding in the fetal human colon is also notewor- 
thy since colonic epithelial cells exhibited even 
higher EGF binding than their intestinal counter- 
parts. A similar observation was also noted in an 
earlier study involving EGF receptors during 
postnatal development of mouse colon [16]. This 
higher binding in colonic epithelial cells can be at- 
tributed partly to a higher concentration of EGF 
116 
receptors on their cell surface. Since the onset of 
villus formation and epithelial differentiation in 
the developing colon occurs 3-4 weeks after initia- 
tion of morphogenesis in the small intestine, there 
may exist a relation between the fact that levels of 
EGF binding in the colon at 17 weeks coincide with 
peak levels observed in the 12-14-week-old in- 
testine (fig.2). The presence of specific EGF recep- 
tors in human fetal small intestine and colon 
certainly lend further support to an important role 
of EGF in human gut development. Indeed, EGF, 
along with other hormonal supplements, has 
recently been shown to enhance differentiation of 
human fetal intestine in organ culture [21] as well 
as in serially passaged human fetal normal colonic 
epithelial cells [22]. The use of human colonic car- 
cinoma lines may also provide additional informa- 
tion since several of these moderately 
well-differentiated cell lines exhibit increased ex- 
pression of EGF receptors [23]. 
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